U.S. Medical Equipment Stock News

Summit Therapeutics has expanded its global registration-enabling program for ivonescimab by initiating the HARMONi-GU1 Phase II/III trial in previously untreated locally advanced or metastatic urothelial (bladder) cancer, comparing ivonescimab plus enfortumab vedotin against the current standard pembrolizumab plus enfortumab vedotin. This move adds bladder cancer to Summit’s growing list of tumor types for ivonescimab and further tests whether its bispecific PD-1/VEGF design can offer...

Portillo's stock barely budged after earnings, up just 1% to about US$4.43, even as the quarter put the company’s biggest pressure point into sharper focus. Same restaurant sales slipped 1.2% while restaurant level margins compressed, with food, beverage and packaging costs now at 35% of revenue. That is the short term story. The long term question is whether Portillo's can offset that cost squeeze through slower unit growth, a leaner store prototype and the US$10 to US$15 million of annual...

Allstate shareholders woke up to a reality check. The stock slipped almost 3% to about US$267 even though the insurer just printed another quarter of heavy profits and tight underwriting. Q2 adjusted earnings landed at US$8.99 per share, with net income of US$3.2b and a Property and Casualty combined ratio of 86.6%, which points to solid profitability for an insurer. The stock has run hard over the past three months and then cooled on the day, right as Allstate posted strong income and...

What the Raytheon SM-3 contract means for Voyager Technologies stock Voyager Technologies (VOYG) has drawn fresh attention after Raytheon, an RTX business, awarded the company a contract to supply propulsion and divert, attitude and control systems for the Standard Missile 3 interceptor family. This contract highlights Voyager Technologies’ role in solid propulsion and precision maneuvering systems for missiles and space payloads, which already sit at the core of its Defense & National...

Check Point Software Technologies (CHKP) drew investor attention after reporting second quarter 2026 results, issuing third quarter revenue guidance, launching its AI Network Firewall, and updating progress on a long running share repurchase plan. See our latest analysis for Check Point Software Technologies. The recent 1-day share price return of 2.03% and 7-day share price return of 0.54% suggest a short-term rebound after a 30-day share price return that declined 6.60%. However, the 1-year...

China’s trade surplus is widening, helped by AI related exports even as tariff frictions linger. That highlights how powerful the ChatGPT and AI wave has become for companies supplying chips, software, cloud and large language models. Investors who ignore this theme risk missing some of the most discussed growth stories of this cycle. This article walks through 3 AI stocks from the screener that many investors are watching closely. The 3 stocks below are just a sample, and the full screen...

Helios Technologies (HLIO) is in focus after Wall Street analysts issued fresh projections for its upcoming quarter, including an earnings per share estimate of $0.80 and revenue expectations implying 8.4% year over year growth. See our latest analysis for Helios Technologies. Against this backdrop of higher earnings expectations, Helios Technologies’ share price of $82.32 follows a 7 day share price return of 5.93% and a 90 day share price return of 20.67%. The 1 year total shareholder...

Weyerhaeuser (WY) is back in focus after reporting second quarter 2026 earnings, with net income of US$162 million and earnings per share of US$0.23 from continuing operations, both higher than a year earlier. See our latest analysis for Weyerhaeuser. Despite a 1-day share price return that declined 1.5% to US$25.45, Weyerhaeuser has gained 8.3% over the past week and 9.3% over the past month, suggesting short term momentum has picked up even though the 1-year total shareholder return of 2.5%...

Ternium (NYSE:TX) stock is in focus after Q2 2026 results showed higher sales, an increase in adjusted EBITDA margin to 16.5%, and an earnings surprise versus analyst expectations. See our latest analysis for Ternium. The Q2 earnings surprise and margin improvement appear to have reinforced interest in Ternium, with the share price at US$51.89 after a 21.38% 1 month share price return and a 75.22% 1 year total shareholder return, suggesting momentum has been building. If the recent move in...

With the US unexpectedly losing 23,000 jobs in July and wage growth slowing while inflation sits at 3.5%, shoppers may start stretching every dollar. That shift in behavior can matter a lot for certain stocks that are tied to value focused spending. This article walks through three stocks from our Discount Retailers and Value Chains screener that appear particularly exposed to these labor market and inflation trends. The three stocks covered below are just a small sample, and the full screen...

CoreCivic’s share price has surged over the last few years, yet the stock currently screens as expensive on broad valuation checks, which leaves investors weighing strong recent returns against a low value score. CoreCivic has returned 213.0% over the past 3 years, which puts recent gains front and center for anyone assessing whether the current share price still offers value. New contracts and facility sales that strengthen the balance sheet and may support future cash generation now sit...

Cintas (NasdaqGS: CTAS) announced a leadership change, appointing Jim Rozakis as President while Todd Schneider continues as CEO. The company has formally separated the President and CEO roles, signaling a new executive structure for the business. Consider broadening your watchlist with other companies in similar industries through 78 resilient stocks with low risk scores NasdaqGS:CTAS 1-Year Stock Price Chart Cintas operates in the uniform rental and facility services space, an area that...

Collegium Pharmaceutical stock has delivered a 59.8% gain over the past five years, yet the recent share price pullback and a strong set of valuation checks suggest the market may be reassessing how cheap or expensive the current price really is. Over five years, Collegium Pharmaceutical has returned 59.8%, which points to meaningful value creation for longer term holders despite more recent weakness. Future growth in prescriptions and cash flow can support the current market value, while...

Unity Software stock has rebounded in the short term, yet the valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market based multiples suggest the shares screen as expensive. After a multi year period where the share price declined 67.8% over 5 years, investors now face a gap between what the DCF implies and what traditional valuation checks are signaling. Unity Software shareholders have seen the stock decline 67.8% over 5...

JetBlue Airways (JBLU) has been in focus after reporting higher second quarter 2026 revenue along with a wider net loss, updating its operating guidance, setting a 2028 EPS target, and filing a US$121.4 million shelf registration. See our latest analysis for JetBlue Airways. At a share price of US$6.19, JetBlue Airways has seen a 30 day share price return of 8.22% and a 90 day share price return of 21.14%. The 1 year total shareholder return of 43.29% contrasts with weaker 3 and 5 year total...

Salesforce stock has fallen 26.4% year to date, yet on the current checks it still screens as relatively cheap compared with its fundamentals. This sets up a clear question about whether the recent share price is fully reflecting the business outlook. Year to date the share price is down 26.4%, which puts Salesforce on the back foot even after recent short term gains. Large public sector AI deals and expanding use of its Agentforce and Missionforce platforms can support growth expectations,...

Amylyx Pharmaceuticals (AMLX) shares moved after the company reported second quarter 2026 results, which showed a net loss of US$43.42 million and basic loss per share from continuing operations of US$0.39. See our latest analysis for Amylyx Pharmaceuticals. The latest earnings update appears to have sharpened attention on Amylyx Pharmaceuticals, with the share price at US$24.19 and a 1-day share price return of 10.71%, building on a 30-day share price return of 33.13% and a 1-year total...

H2O America stock has delivered a 27.2% return over the past year, yet the latest valuation work, including the Dividend Discount Model (DDM) intrinsic value estimate and earnings-based multiples, both suggest the shares trade at a premium rather than at a discount. Over the last 12 months H2O America is up 27.2%, which puts recent shareholders in profit while raising the question of how much optimism is already in the price. Expectations around growth from the planned Quadvest acquisition...

BXP (BXP) shares are in focus after the company closed a $1.2b construction loan tied to its 343 Madison Avenue project in Midtown Manhattan, a key financing step for the $2b development. See our latest analysis for BXP. The construction loan news lands after a mixed share price run for BXP, with a 90 day share price return of 15.78% but a 5 year total shareholder return that is still down 24.13%. Recent events include the updated 2026 earnings guidance, second quarter results, and the...

Second quarter earnings put Littelfuse stock in focus Littelfuse (LFUS) is back in the spotlight after its second quarter report on July 29, 2026. The release combined higher sales, increased net income and updated guidance, alongside a raised quarterly dividend. The company reported second quarter sales of US$738.78 million compared with US$613.41 million a year earlier. Net income was US$89.41 million compared with US$57.34 million, with diluted earnings per share from continuing operations...

HF Sinclair stock has more than tripled over the past five years, yet its valuation checks still lean cheap, which raises a clear question over how much of that past share price strength is already reflected in today's price. With investors also weighing the planned separation of the Lubricants & Specialties segment and the closure of Canada's largest base oil refinery, the current market value is under close scrutiny. HF Sinclair has delivered a 224.8% return over the last five years, which...

Watts Water Technologies stock reacts to earnings, guidance and capital returns Watts Water Technologies (WTS) just delivered second quarter 2026 results, raised its full year guidance, updated investors on share repurchases, and affirmed its quarterly dividend, providing several fresh data points to assess. See our latest analysis for Watts Water Technologies. The earnings beat and raised 2026 guidance appear to have reinforced confidence in Watts Water Technologies, with a 1 day share price...

Why Getty Realty’s New Accounting Chief Matters For Investors Getty Realty (GTY) has announced a leadership change in its finance function, appointing Nicole Rapport as Vice President and Chief Accounting Officer as of August 16, 2026, replacing long-time executive Eugene Shnayderman. The company states that Shnayderman’s departure does not stem from disagreements over accounting principles, financial reporting, or disclosure. For investors tracking governance and reporting quality, this...

Why Corcept Therapeutics stock is back in focus after Q2 earnings Corcept Therapeutics (CORT) is drawing fresh attention after its July 29 earnings update, which paired detailed second quarter results with higher full year 2026 revenue guidance and a buyback progress report. See our latest analysis for Corcept Therapeutics. Corcept Therapeutics’ share price has eased in the very short term, with a 1 day share price return of 2.48% and a 7 day share price return of 8.76%. However, the 30 day...